GSK plc files 6-K

GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) as an add-on therapy for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) for whom current treatments are inadequate. This follows the recent approval of Exdensur in China for severe asthma.